22:30:18 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-20 Bokslutskommuniké 2024
2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 X-dag ordinarie utdelning DIGN 0.00 SEK
2024-05-23 Årsstämma 2024
2024-05-23 Kvartalsrapport 2024-Q1
2024-03-12 Extra Bolagsstämma 2024
2024-02-15 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 X-dag ordinarie utdelning DIGN 0.00 SEK
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-25 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-20 X-dag ordinarie utdelning DIGN 0.00 SEK
2022-05-19 Årsstämma 2022
2022-05-19 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-21 X-dag ordinarie utdelning DIGN 0.00 SEK
2021-05-20 Årsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2021-01-11 Extra Bolagsstämma 2021
2020-11-19 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-26 X-dag ordinarie utdelning DIGN 0.00 SEK
2020-06-25 Årsstämma 2020
2020-05-28 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019
2020-02-10 Extra Bolagsstämma 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-16 X-dag ordinarie utdelning DIGN 0.00 SEK
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-15 Årsstämma 2019
2019-02-26 Bokslutskommuniké 2018
2018-11-27 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-05-22 Kvartalsrapport 2018-Q1
2018-04-27 X-dag ordinarie utdelning DIGN 0.00 SEK
2018-04-26 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-12-04 Extra Bolagsstämma 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-06-02 Årsstämma 2017
2017-05-24 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-11-24 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-25 Kvartalsrapport 2016-Q1
2016-03-23 X-dag ordinarie utdelning DIGN 0.00 SEK
2016-03-22 Årsstämma 2016
2016-02-24 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-05-19 X-dag ordinarie utdelning DIGN 0.00 SEK
2015-02-24 Bokslutskommuniké 2014
2014-11-25 Kvartalsrapport 2014-Q3
2014-08-26 Kvartalsrapport 2014-Q2
2014-05-20 Kvartalsrapport 2014-Q1
2014-05-19 X-dag ordinarie utdelning DIGN 0.00 SEK
2014-05-16 Årsstämma 2014
2014-03-04 Extra Bolagsstämma 2014
2014-02-27 Bokslutskommuniké 2013
2013-11-28 Kvartalsrapport 2013-Q3
2013-08-28 Kvartalsrapport 2013-Q2
2013-08-28 Extra Bolagsstämma 2013
2013-05-22 Kvartalsrapport 2013-Q1
2013-05-22 X-dag ordinarie utdelning DIGN 0.00 SEK
2013-05-21 Årsstämma 2013
2013-02-27 Bokslutskommuniké 2012
2012-11-28 Kvartalsrapport 2012-Q3
2012-10-30 Extra Bolagsstämma 2012
2012-09-28 Kapitalmarknadsdag 2012
2012-08-28 Kvartalsrapport 2012-Q2
2012-06-29 Årsstämma 2012
2012-05-28 Kvartalsrapport 2012-Q1
2012-02-27 Bokslutskommuniké 2011
2011-11-17 Kvartalsrapport 2011-Q3
2011-08-22 Kvartalsrapport 2011-Q2
2011-06-13 X-dag ordinarie utdelning DIGN 0.00 SEK
2011-06-10 Årsstämma 2011
2011-05-30 Kvartalsrapport 2011-Q1
2011-02-25 Bokslutskommuniké 2010
2010-11-18 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-06-21 X-dag ordinarie utdelning DIGN 0.00 SEK
2010-05-18 Kvartalsrapport 2010-Q1
2010-02-18 Bokslutskommuniké 2009
2009-12-21 Split DIGN 100:1
2009-11-18 Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Dignitana är verksamt inom medicinteknik. Bolaget utvecklar, tillverkar och marknadsför medicinska hjälpmedel som primärt används som skalpkylningssystem vid cytostatikabehandling, vars syfte är att eliminera eller kraftigt reducera håravfall. Bolaget har global verksamhet främst inom Norden, Europa, Nordamerika och Asien. Dignitana grundades år 2007 och har sitt huvudkontor i Lund.
2022-02-17 08:00:00

Continued US growth fuels 25 percent revenue increase

Financial highlights Q4 2021
  • Net sales amounted to 16.2 MSEK (12.9), an increase of 25 percent over the same period 2020.
  • Operating result amounted to -11.4 MSEK (-19.7).
  • Net result after financial items amounted to -11.8 MSEK (-20.8).
  • Earnings per share were -0,18 SEK (-0,37).
  • Cash Balance amounted to 14.5 MSEK (78.8).
  • Average Daily Treatment Revenue (ADTR)* was 155 TSEK (130), an increase of 19 percent over the same period in 2020.
Financial highlights January - December 2021
  • Net sales amounted to 57.1 MSEK (46.6), an increase of 22 percent over the same period 2020.
  • Operating result amounted to -41.6 MSEK(-50.7).
  • Net result after financial items amounted to -43.1 MSEK (-53.0).
  • Earnings per share were -0,66 SEK (-0,96).
  • Cash Balance amounted to 14.5 MSEK (78.8).
  • Average Daily Treatment Revenue (ADTR)* was 147 TSEK (120), an increase of 22 percent over the same period in 2020.
  • Impacting operating results, the Company has taken non-recurring cost of 9.6 MSEK in 2021 related to Quality System and Market Access improvements.
Significant events during the period
  • Dignitana announced a decision from Medicare enabling reimbursement to cancer centers providing DigniCap to chemotherapy patients in the US effective 1 January 2022.
  • In December Dignitana CEO William Cronin notified the Board of Directors of his intention to resign as CEO in May.
Business highlights during the period
  • Five DigniCap patients were recognized as DigniCap Dignitaries during Breast Cancer Awareness month and interviewed in weekly Facebook Live broadcasts in October.
  • Dignitana CEO William Cronin spoke at Erik Penser Bank's Bolagsdag in November 2021, addressing the Company's overall growth strategy and the significance of recent reimbursement initiatives in the US, including the January 2022 Medicare classification for scalp cooling.
  • Dignitana exhibited at the San Antonio Breast Cancer Symposium in December.
Significant events after the period
  • The Board appointed Catarina Mård Löwenadler as the new CEO of Dignitana. She has extensive experience from leading positions in both MedTech and sales and will take over as CEO after the Annual General Meeting in May.
  • The company had previously announced that Magnus Blixt would become CEO, however he chose not to take the role due to personal reasons.
  • The company named Alf Christensson as Interim CFO and he will assume the role 1 March 2022.
Business highlights after the period
  • Dignitana CEO William Cronin will address the Stockholm Corporate Finance Life Science Capital Markets Days on 9 March, providing an update on the company's strategic growth and discuss current reimbursement initiatives.
  • Continuing the partnership with Susan G Komen®, in March Dignitana will sponsor the More than Pink Walk in Orlando, Florida.

Key Figures

DIGNITANA GROUP Q4 2021 Q4 2020 Full year 2021 Full year 2020
Net sales, TSEK 16 213 12 928 57 073 46,629
Total revenues, TSEK 17 322 13 006 62 376 49,956
Net profit after -11 836 -20 821 -43 076 -52,963
financial items, TSEK
Cash and bank balances, 14 501 78 770 14 501 78,770
TSEK
Earnings per share -0,18 -0,37 -0,66 -0,96
before and after
dilution, SEK
Average Daily Treatment 155 130 147 120
revenue*, TSEK

* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

"During these challenging times our company has continued to  grow and adapt to the unique and generational challenges we face." -William Cronin, CEO Dignitana AB

All financial reports are available at www.dignitana.com/investor-relations/financial-reports/

This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-02-2022 08:00 CET.